menu
    • menu
    [{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Zhongnan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ACT500","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Zhongnan Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Zhongnan Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Drug Farm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ALG-000184","moa":"||Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Inpegsomatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"YPEG-rhG-CSF","moa":"G-CSF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Cancer Institute and Hospital, Chinese Academy of Medical Sciences"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Somatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"9","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"First Affiliated Hospital of Zhejiang University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"YPEG-rhEPO","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ First Affiliated Hospital of Zhejiang University","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ First Affiliated Hospital of Zhejiang University"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"YPEG-rhGH","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Tongji Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telpegfilgrastim","moa":"G-CSF receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Telpegfilgrastim","moa":"G-CSF receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University Third Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"2","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Xiamen Amoytop Biotech Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Xiamen Amoytop Biotech Co., Ltd

    Menu

    Xiamen Amoytop Biotech Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DF-006

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Drug Farm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Drug Farm and Amoytop Ink Option Deal for DF-006 To Treat Hepatitis B and Liver Cancer

                            Details : The collaboration aims to advance the clinical development of Drug Farm’s first-in-class ALPK1 agonist, DF-006 in the field of ​hepatitis B and hepatocellular cancer in the ​Greater China region.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : DF-006

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Drug Farm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inpegsomatropin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Inpegsomatropin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telpegfilgrastim

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Peking University Third Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 11, 2025

                            Lead Product(s) : Telpegfilgrastim

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Peking University Third Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telpegfilgrastim

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Peking University Third Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : Telpegfilgrastim

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Peking University Third Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACT500

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Zhongnan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : ACT500

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Zhongnan Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa-2B

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Interferon Alfa-2B

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Alfa-2B

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 14, 2024

                            Lead Product(s) : Interferon Alfa-2B

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALG-000184,Mipeginterferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Aligos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

                            Details : Amoytop will sponsor a Phase 1b exploratory study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING (Mipeginterferon alfa-2b) in chronic hepatitis B patients in China.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : ALG-000184,Mipeginterferon Alpha-2b

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Aligos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery

                            Recipient : Aligos Therapeutics

                            Deal Size : $109.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co....

                            Details : Under the terms of the agreement, Aligos and Amoytop will use Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery

                            Recipient : Aligos Therapeutics

                            Deal Size : $109.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed

                            Xiamen Amoytop Biotech Co., Ltd

                            China arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YPEG-rhGH

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of YPEG-rhGH in Children With Short Stature

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : YPEG-rhGH

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth